StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

Parabilis’ IPO surpasses the $625 million IPO carried out in April by Kailera Therapeutics, which topped the previous record-high among U.S. biotechs, the $604 million offering of Moderna in December 2018, two years before the messenger RNA (mRNA) vaccine developer won FDA emergency authorization for its COVID-19 vaccine.

The post StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO appeared first on GEN - Genetic Engineering and Biotechnology News.